Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Public members of STANDING Together reflect on their experience in developing standards to tackle bias in health technologies that use artificial intelligence.
Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health.
A new AI generative model leverages the use of synthetic images to effectively augment existing datasets, boosting performance across multiple medical applications
In a cluster analysis study, we identified two types of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by distinct clinical trajectories. The two types of MASLD show similar liver histology, but one is liver-specific with low cardiovascular risk while the other has high cardiovascular risk and high metabolic risk.
Partitioning clustering based on clinical variables applied to multiple patient cohorts identifies two subtypes of metabolic dysfunction-associated steatotic liver disease with different associations to hepatic and cardiovascular outcomes.
The application of partitioned polygenic scores to data from cohorts of patients identifies two distinct subtypes of MASLD with different cardiometabolic risk profiles.
The vascular system has many different functions across the human body beyond its role in oxygen and nutrient transport. We explored vascular cell heterogeneity by integrating single-cell RNA-sequencing data from the Human Cell Atlas and ongoing collaborations across 19 healthy human organs and tissues, and highlight shared and distinct molecular features of vascular beds.
Nature Medicine asks experts to explain the research priorities for the field of GLP-1 receptor agonists such as semaglutide, from sex differences to how they might treat addiction.
